Last reviewed · How we verify
NCT05035615
Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer
trial testing IUO Acute Leukemia Panel in Acute Leukemia in 332 participants. Completed in 18 July 2024.
29 June 2024
Quick facts
| Lead sponsor | Becton, Dickinson and Company |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 332 |
| Start date | 2 November 2021 |
| Primary completion | 29 June 2024 |
| Estimated completion | 18 July 2024 |
| Sites | 8 locations across Brazil, United Kingdom, United States, Spain, Czechia |
Drugs / interventions tested
- IUO Acute Leukemia Panel
Conditions studied
- Acute Leukemia — all drugs for Acute Leukemia →
Sponsor
Becton, Dickinson and Company — full company profile →
Who can join
3 and older, any sex, with Acute Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multi-site, prospective performance study to determine equivalency between the investigational OneFlow Acute Leukemia Panel on the FACSLyric system versus the final clinical diagnosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05035615
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Leukemia
Currently open trials in the same condition.
- NCT07270770 — BY002 IIT Study in R/R Acute Leukemia · Phase 1 · recruiting
- NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
- NCT07362095 — Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) · Phase 1, PHASE2 · recruiting
- NCT07101497 — Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia · Phase 2 · recruiting
- NCT06984536 — Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT · Phase 2 · recruiting
Other Becton, Dickinson and Company trials
Trials by the same sponsor.
- NCT06632509 — BD SiteRite(TM) 9 Ultrasound System - Clinical Study · completed
- NCT06632496 — BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study · completed
- NCT06604026 — Investigational Study With the BD PosiFlush™ SafeScrub on NADs · NA · recruiting
- NCT06426121 — Clinical Validation of BACTEC™ Plus Aerobic/F Culture Vials Compared With Equivalent Product · completed
- NCT05953363 — Prospective Clinical Evaluation of BD NRFit™ Devices and Accessories. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05035615 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Becton, Dickinson and Company
- Last refreshed: 6 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05035615.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing